Equillium (EQ) Stock Price, News & Analysis

Company Overview

Equillium, Inc. (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies. The company has since advanced EQ001 through Phase 1 and Phase 2 clinical trials, evaluating its potential in steroid-refractory acute GVHD and exploring additional autoimmune indications, such as ulcerative colitis. Equillium’s R&D strategy emphasizes rigorous clinical development and targeted patient populations to address areas of high unmet medical need.

Equillium conducts its clinical trials and research activities primarily in the United States, collaborating with leading academic institutions and transplant centers. The company’s global development plan includes potential partnerships or licensing arrangements to expand access to its therapies beyond North America. Equillium maintains a focused corporate structure designed to streamline decision-making and support efficient execution of its clinical programs.

Under the leadership of President and Chief Executive Officer Roger Pomerantz, Equillium has built a management team with deep expertise in immunology, clinical development, and regulatory affairs. The company’s board and scientific advisory committee include seasoned industry professionals who guide Equillium’s strategic direction. As a clinical-stage enterprise, Equillium remains committed to advancing its immunotherapy candidates through pivotal trials and towards regulatory approval for patients in need.

Key Stats

• Today's Range: $1.19 to $1.55
• 50-Day Range: $0.89 to $1.99
• 52-Week Range: $0.27 to $2.35
• Volume: 2.78 million shs
• Average Volume: 687,186 shs
• Market Capitalization: $86.87 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.00
• Consensus Rating: Reduce

Equillium Stock Analysis - MarketRank™

Equillium scored higher than 9% of companies evaluated by MarketBeat, and ranked 917th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Equillium has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no buy ratings, 2 hold ratings, and 1 sell rating.

Downside Risk

Equillium has a consensus price target of $1.00, representing about 31.5% downside from its current price of $1.46.

Amount of Analyst Coverage

Equillium has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Equillium are expected to decrease in the coming year, from $0.14 to ($0.81) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Equillium is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Equillium is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Equillium has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.66% of the outstanding shares of Equillium have been sold short.

Short Interest Ratio / Days to Cover

Equillium has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Equillium has recently increased by 55.71%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Equillium does not currently pay a dividend.

Dividend Growth

Equillium does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.66% of the outstanding shares of Equillium have been sold short.

Short Interest Ratio / Days to Cover

Equillium has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Equillium has recently increased by 55.71%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Sentiment

Equillium has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Equillium this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added Equillium to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Equillium insiders have not sold or bought any company stock.

Percentage Held by Insiders

31.60% of the stock of Equillium is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 27.05% of the stock of Equillium is held by institutions.

EQ Stock Analysis - Frequently Asked Questions

How have EQ shares performed this year?

Equillium's stock was trading at $0.7482 on January 1st, 2025. Since then, EQ shares have increased by 95.1% and is now trading at $1.46.

How were Equillium's earnings last quarter?

Equillium, Inc. (NASDAQ:EQ) issued its earnings results on Thursday, August, 14th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.02.

When did Equillium IPO?

Equillium (EQ) raised $70 million in an initial public offering (IPO) on Friday, October 12th 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and Stifel acted as the underwriters for the IPO.

How do I buy shares of Equillium?

Shares of EQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Equillium own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Equillium investors own include NVIDIA (NVDA), Meta Platforms (META), Bank of America (BAC), Advanced Micro Devices (AMD), AbbVie (ABBV), Tilray Brands (TLRY) and Carnival (CCL).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 10/19/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EQ
• CIK: 1746466
• Web: equilliumbio.com
• Phone: (858) 240-1200
• Fax: N/A
• Employees: 40
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Equillium: $1.00
• High Price Target: $1.00
• Low Price Target: $1.00
• Potential Upside/Downside: -31.5%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 10.43
• P/E Growth: N/A
• Net Income: -$8.07 million
• Net Margins: N/A
• Pretax Margin: -119.82%
• Return on Equity: -139.56%
• Return on Assets: -90.56%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.65
• Quick Ratio: 1.65

Sales & Book Value

• Annual Sales: $41.10 million
• Price / Sales: 2.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.54 per share
• Price / Book: 2.70

Miscellaneous

• Outstanding Shares: 59,500,000
• Free Float: 40,700,000
• Market Cap: $86.87 million
• Optionable: Not Optionable
• Beta: 1.53